Cardiome Will Develop Eli Lilly Compound to Treat Cardiogenic Shock
May 1, 2007 — Cardiome Pharma Corp. says this week it has received exclusive worldwide rights to Eli Lilly & Co.'s protein GED-aPC, which will initially be developed as cardiogenic shock treatment.
The Associated Press reports that Cardiome will pay Eli Lilly $20 million upfront and future development milestones of up to $40 million. Eli Lilly is entitled to royalty payments if the molecule is commercialized. Cardiome said clinical costs for the compound will be about $5 million in 2007.
The compound has anti-inflammatory and anti-thrombotic properties. Eli Lilly has already finished an early-stage clinical trial on the drug.